Your browser doesn't support javascript.
Effect of time and titer in convalescent plasma therapy for COVID-19.
de Candia, Paola; Prattichizzo, Francesco; Garavelli, Silvia; La Grotta, Rosalba; De Rosa, Annunziata; Pontarelli, Agostina; Parrella, Roberto; Ceriello, Antonio; Matarese, Giuseppe.
  • de Candia P; IRCCS MultiMedica, 20138 Milano, Italy.
  • Prattichizzo F; IRCCS MultiMedica, 20138 Milano, Italy.
  • Garavelli S; Istituto per l'Endocrinologia e l'Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Naples, Italy.
  • La Grotta R; IRCCS MultiMedica, 20138 Milano, Italy.
  • De Rosa A; Dipartimento di Malattie Infettive ed Emergenze Infettive, Divisione di Malattie Infettive Respiratorie, Ospedale Cotugno, AORN dei Colli, 80131 Naples, Italy.
  • Pontarelli A; Dipartimento di Malattie Infettive ed Emergenze Infettive, Divisione di Malattie Infettive Respiratorie, Ospedale Cotugno, AORN dei Colli, 80131 Naples, Italy.
  • Parrella R; Dipartimento di Malattie Infettive ed Emergenze Infettive, Divisione di Malattie Infettive Respiratorie, Ospedale Cotugno, AORN dei Colli, 80131 Naples, Italy.
  • Ceriello A; IRCCS MultiMedica, 20138 Milano, Italy.
  • Matarese G; Istituto per l'Endocrinologia e l'Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Naples, Italy.
iScience ; 24(8): 102898, 2021 Aug 20.
Article in English | MEDLINE | ID: covidwho-1322153
ABSTRACT
The clinical benefit of convalescent plasma (CP) for patients with coronavirus disease (COVID)-19 is still debated. In this systematic review and meta-analysis, we selected 10 randomized clinical trials (RCTs) and 15 non-randomized studies (total number of patients = 22,591) of CP treatment and evaluated two different scenarios (1) disease stage of plasma recipients and (2) donated plasma antibody titer, considering all-cause mortality at the latest follow-up. Our results show that, when provided at early stages of the disease, CP significantly reduced mortality risk ratio (RR) 0.72 (0.68, 0.77), p < 0.00001, while provided in severe or critical conditions, it did not (RR 0.94 [0.86, 1.04], p = 0.22). On the other hand, the benefit on mortality was not increased by using plasma with a high-antibody titer compared with unselected plasma. This meta-analysis might promote CP usage in patients with early-stage COVID-19 in further RCTs to maximize its benefit in decreasing mortality, especially in less affluent countries.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Language: English Journal: IScience Year: 2021 Document Type: Article Affiliation country: J.isci.2021.102898

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Language: English Journal: IScience Year: 2021 Document Type: Article Affiliation country: J.isci.2021.102898